181 related articles for article (PubMed ID: 37741446)
1. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis.
Jansen JP; Ragavan MV; Chen C; Douglas MP; Phillips KA
Value Health; 2023 Dec; 26(12):1697-1710. PubMed ID: 37741446
[TBL] [Abstract][Full Text] [Related]
2. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.
Englmeier F; Bleckmann A; Brückl W; Griesinger F; Fleitz A; Nagels K
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1495-1511. PubMed ID: 35532791
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.
Kowal S; Ng CD; Schuldt R; Sheinson D; Cookson R
Value Health; 2023 Feb; 26(2):216-225. PubMed ID: 36192293
[TBL] [Abstract][Full Text] [Related]
5. Cell-Free Circulating Tumour DNA Blood Testing to Detect
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
Liu S; Graves N; Tan AC
Lung Cancer; 2024 May; 191():107794. PubMed ID: 38636314
[TBL] [Abstract][Full Text] [Related]
7. The Health Inequality Impact of a New Cancer Therapy Given Treatment and Disease Characteristics.
Jansen JP; Brewer IP; Chung S; Sullivan P; Espinosa OD; Grossman JP
Value Health; 2024 Feb; 27(2):143-152. PubMed ID: 37952840
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Intervention Impact on Health Inequality for Resource Allocation.
Griffin S; Love-Koh J; Pennington B; Owen L
Med Decis Making; 2019 Apr; 39(3):171-182. PubMed ID: 30819034
[TBL] [Abstract][Full Text] [Related]
9. Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.
Jiang Y; Zhao M; Liu R; Zheng X
Medicine (Baltimore); 2023 Dec; 102(50):e36387. PubMed ID: 38115313
[TBL] [Abstract][Full Text] [Related]
10. Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities.
Quan AML; Mah C; Krebs E; Zang X; Chen S; Althoff K; Armstrong W; Behrends CN; Dombrowski JC; Enns E; Feaster DJ; Gebo KA; Goedel WC; Golden M; Marshall BDL; Mehta SH; Pandya A; Schackman BR; Strathdee SA; Sullivan P; Tookes H; Nosyk B;
Lancet HIV; 2021 Sep; 8(9):e581-e590. PubMed ID: 34370977
[TBL] [Abstract][Full Text] [Related]
11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
Mfumbilwa ZA; Simons MJHG; Ramaekers B; Retèl VP; Mankor JM; Groen HJM; Aerts JGJV; Joore M; Wilschut JA; Coupé VMH
Pharmacoeconomics; 2024 Apr; 42(4):419-434. PubMed ID: 38194023
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
14. Explorative cost-effectiveness analysis of colorectal cancer recurrence detection with next-generation sequencing liquid biopsy in Spain, France, and Germany.
Schramm W; Hollenbenders Y; Kurscheidt M
Therap Adv Gastroenterol; 2024; 17():17562848241248246. PubMed ID: 38737912
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
Front Public Health; 2021; 9():743558. PubMed ID: 34957008
[No Abstract] [Full Text] [Related]
16. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
Li F; Chen Y; Xiao D; Jiang S; Yang Y
Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
19. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.
Ezeife DA; Spackman E; Juergens RA; Laskin JJ; Agulnik JS; Hao D; Laurie SA; Law JH; Le LW; Kiedrowski LA; Melosky B; Shepherd FA; Cohen V; Wheatley-Price P; Vandermeer R; Li JJ; Fernandes R; Shokoohi A; Lanman RB; Leighl NB
Ther Adv Med Oncol; 2022; 14():17588359221112696. PubMed ID: 35923926
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.
Mosher CL; Nanna MG; Jawitz OK; Raman V; Farrow NE; Aleem S; Casaburi R; MacIntyre NR; Palmer SM; Myers ER
JAMA Netw Open; 2022 Jun; 5(6):e2218189. PubMed ID: 35731514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
